Loading
Regulatory decisions, advisory committees, expected trial readouts, and the congresses where results land. Confirmed items carry a source. Expected items are our editorial estimate from trial registrations and sponsor statements, and can slip by quarters. Below the timeline, registry changes detected by the weekly ClinicalTrials.gov snapshot wait for editorial review.
Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee reviews GRAIL's premarket approval application. The first FDA-level judgement on a multi-cancer blood screening test.
SourceEurope's largest oncology congress. Watch for: TROPION-Breast05, first-line ADC + IO data, late-breaking radioligand and bispecific ADC results.
SourceThe breast cancer congress. Post-neoadjuvant TNBC ADC trials (ASCENT-05, TROPION-Breast03) and sac-TMT first-line TNBC data are candidates for presentation here or at ESMO.
Haematology's main congress: CAR-T, bispecifics, menin inhibitors, BCL-2 combinations.
Primary completion per registry falls in 2026; timing of topline is our estimate. Would complete the ADC + IO first-line picture alongside ASCENT-04.
SourceTopline positive 19 August 2026; hazard ratios and curves expected at a late-2026 congress (ESMO or SMR), with regulatory filings to follow.
SourceFull results presented at ASCO 2026 (primary stage III to IV endpoint not met; stage IV reduction reported). NHS England said it would wait for final results before any rollout decision; timing of a decision is not announced.
SourceFully enrolled; event-driven OS endpoint. Sponsor has guided to a readout in 2026 or 2027. The first pivotal test of a pan-RAS inhibitor.
SourceEarly science and first-in-human data: next-generation ADC payloads, degraders, in vivo CAR-T.
SourceWhere most practice-changing phase 3 trials are first presented.
SourceGlobal first-line trial of the EGFR×HER3 bispecific ADC; timing is an estimate from enrolment start (2025).
SourceRegistry estimated primary completion 20 September 2027; topline may lag.
SourceMerck holds a Commissioner's National Priority Voucher (July 2026) that promises a 1 to 2 month review once filed. No PDUFA date has been disclosed; indication (TNBC vs EGFR-mutant NSCLC) and filing timing are not public.
SourceEvent-driven iDFS endpoint in patients with residual disease after KEYNOTE-522-type therapy. Would be the first ADC in the curative TNBC setting.
Detected automatically by diffing weekly ClinicalTrials.gov snapshots for every product: status moves, newly posted results and moved primary completion dates. These are expected events, not confirmed ones, until an editor checks them and adds a dated calendar entry.
Missing a date? Add it to src/data/calendar.ts with a source. Expected readouts become confirmed only when a sponsor or registry gives a date.